FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286295095> ?p ?o ?g. }

• W4286295095 endingPage "e19576" @default.
• W4286295095 startingPage "e19576" @default.
• W4286295095 abstract "e19576 Background: Polatuzumab vedotin (POLA) is an antibody–drug conjugate composed of an anti-CD79b monoclonal antibody conjugated by a protease-cleavable linker to monomethyl auristatin E, a microtubule inhibitor. POLA has shown efficacy in patients with relapsed or refractory Diffuse large B-Cell lymphoma (DLBCL) and recently shown better progression free survival in previously untreated DLBCL as well. We conducted a meta-analysis of randomized controlled trials (RCTs) to determine the relative risk of neutropenia and febrile neutropenia associated with use of POLA regimens for DLBCL. Methods: We conducted a systematic search at PUBMED, EMBASE, and meeting abstracts as per PRISMA guidelines from 2010 until December 2021. Randomized controlled trial utilizing POLA for DLBCL were included. We used the Mantel-Haenszel (MH) method utilizing random effects model to calculate pooled risk ratio (RR) with 95% confidence interval (CI). Heterogeneity was tested with I 2 value. All statistical analyses were performed with Review Manager Version 5.4. Results: A total of 1073 patients from 3 RCT (1 Phase III and 2 Phase II Studies) were included in this study. The study arm used POLA-R-CHP (Rituximab, Cyclophosphamide, Doxorubicin, Prednisone), POLA-Rituximab, and POLA-BR (Bendamustine-Rituximab). The control arm used R-CHOP, Pinatuzumab-R, and BR respectively The overall incidence of neutropenia was 31.54% in POLA Group vs 32.94% in control group with RR 0.99 (95% CI: 0.69 – 1.42, P=0.97, I 2 =16%) whereas grade 3-4 neutropenia incidence was 29.24 vs 30.82 with RR 0.95 (95% CI: 0.79 – 1.16, P=0.65, I 2 =2%). The overall febrile neutropenia incidence was 12.87% in Polatuzumab group vs 7.90% in the control group with RR 1.62 (95% CI: 1.12 – 2.35, P = 0.01, I 2 =0%). Conclusions: Our study demonstrated that there was no statistical difference in risk ratio of any grade neutropenia (including grade 3-4) in both the arms. However, there was significantly increased risk of febrile neutropenia among patients who received Polatuzumab vedotin based treatment compared to those who did not. Further studies and long term follow up are necessary to define the actual relation and definitive incidence.[Table: see text]" @default.
• W4286295095 created "2022-07-21" @default.
• W4286295095 creator A5003506682 @default.
• W4286295095 creator A5005278836 @default.
• W4286295095 creator A5033198954 @default.
• W4286295095 creator A5046110214 @default.
• W4286295095 creator A5071160880 @default.
• W4286295095 date "2022-06-01" @default.
• W4286295095 modified "2023-10-16" @default.
• W4286295095 title "Neutropenia and neutropenic fever with polatuzumab vedotin for diffuse large B-cell lymphoma: Meta-analysis of randomized clinical trials." @default.
• W4286295095 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e19576" @default.
• W4286295095 hasPublicationYear "2022" @default.
• W4286295095 type Work @default.
• W4286295095 citedByCount "0" @default.
• W4286295095 crossrefType "journal-article" @default.
• W4286295095 hasAuthorship W4286295095A5003506682 @default.
• W4286295095 hasAuthorship W4286295095A5005278836 @default.
• W4286295095 hasAuthorship W4286295095A5033198954 @default.
• W4286295095 hasAuthorship W4286295095A5046110214 @default.
• W4286295095 hasAuthorship W4286295095A5071160880 @default.
• W4286295095 hasConcept C126322002 @default.
• W4286295095 hasConcept C141071460 @default.
• W4286295095 hasConcept C143998085 @default.
• W4286295095 hasConcept C168563851 @default.
• W4286295095 hasConcept C207103383 @default.
• W4286295095 hasConcept C2776694085 @default.
• W4286295095 hasConcept C2777063308 @default.
• W4286295095 hasConcept C2778559949 @default.
• W4286295095 hasConcept C2778850193 @default.
• W4286295095 hasConcept C2779338263 @default.
• W4286295095 hasConcept C2780653079 @default.
• W4286295095 hasConcept C44249647 @default.
• W4286295095 hasConcept C71924100 @default.
• W4286295095 hasConcept C90924648 @default.
• W4286295095 hasConceptScore W4286295095C126322002 @default.
• W4286295095 hasConceptScore W4286295095C141071460 @default.
• W4286295095 hasConceptScore W4286295095C143998085 @default.
• W4286295095 hasConceptScore W4286295095C168563851 @default.
• W4286295095 hasConceptScore W4286295095C207103383 @default.
• W4286295095 hasConceptScore W4286295095C2776694085 @default.
• W4286295095 hasConceptScore W4286295095C2777063308 @default.
• W4286295095 hasConceptScore W4286295095C2778559949 @default.
• W4286295095 hasConceptScore W4286295095C2778850193 @default.
• W4286295095 hasConceptScore W4286295095C2779338263 @default.
• W4286295095 hasConceptScore W4286295095C2780653079 @default.
• W4286295095 hasConceptScore W4286295095C44249647 @default.
• W4286295095 hasConceptScore W4286295095C71924100 @default.
• W4286295095 hasConceptScore W4286295095C90924648 @default.
• W4286295095 hasIssue "16_suppl" @default.
• W4286295095 hasLocation W42862950951 @default.
• W4286295095 hasOpenAccess W4286295095 @default.
• W4286295095 hasPrimaryLocation W42862950951 @default.
• W4286295095 hasRelatedWork W2012238656 @default.
• W4286295095 hasRelatedWork W2018370326 @default.
• W4286295095 hasRelatedWork W2134646407 @default.
• W4286295095 hasRelatedWork W2147757009 @default.
• W4286295095 hasRelatedWork W2149557304 @default.
• W4286295095 hasRelatedWork W2612240035 @default.
• W4286295095 hasRelatedWork W2901183349 @default.
• W4286295095 hasRelatedWork W4212971766 @default.
• W4286295095 hasRelatedWork W4239668963 @default.
• W4286295095 hasRelatedWork W4286295095 @default.
• W4286295095 hasVolume "40" @default.
• W4286295095 isParatext "false" @default.
• W4286295095 isRetracted "false" @default.
• W4286295095 workType "article" @default.